Introduction
============

According to a recent report by the World Health Organization, there are now more than 10 million cases of cancer per year worldwide. Statistics from the American Cancer Society showed that cancer is the third most lethal disease after cardiovascular diseases and infectious and parasitic diseases.[@b1-dddt-8-1659]--[@b4-dddt-8-1659] Cancer refers to a diversity of diseases, characterized by the uncontrolled proliferation of cells into a different form, against the normal complement of the organism.[@b5-dddt-8-1659] The continuous proliferation of cancer cells develops into tumor tissues and may spread across to other organs. The principal need in the chemoprevention of cancer remains the discovery of new agents that are effective and safe.

Sulfur-containing molecules are of particular interest, being widely spread in nature. For example, diallyldisulfide, found in garlic, appears to be potent in protecting against skin, colon, and lung cancer.[@b6-dddt-8-1659]--[@b8-dddt-8-1659] Also, biotin, known as vitamin B7, contains a tetrahydrothiazole ring as an integral part of its structure and acts as an essential cofactor in integral biological metabolic pathways, such as gluconeogenesis, fatty acid synthesis, and amino acid anabolism.[@b9-dddt-8-1659] Bithiophenes and oligothiophenes and their derivatives are important synthetic precursors for biologically active materials.[@b10-dddt-8-1659]--[@b13-dddt-8-1659] Oligothiophene compound α-terthienyl (I) ([Figure 1](#f1-dddt-8-1659){ref-type="fig"}) is considered an anti-infective, antiviral, and photosensitizing agent.[@b14-dddt-8-1659],[@b15-dddt-8-1659]

A number of compounds in this class of aromatic cationic molecules have been shown to bind to the minor groove of DNA at AT-rich sites, and the details of their interaction with the minor groove have been elucidated from biophysical studies,[@b16-dddt-8-1659]--[@b19-dddt-8-1659] including crystal structures.[@b20-dddt-8-1659]--[@b22-dddt-8-1659] It is hypothesized that these types of molecules exert their biological activity by first binding to DNA and then by inhibiting one or more of several DNA-dependent enzymes, or perhaps by direct inhibition of transcription.[@b23-dddt-8-1659],[@b24-dddt-8-1659] Recently, bithiophene diamidines (II) showed good DNA binding affinity and potent antiprotozoal activity,[@b10-dddt-8-1659] whereas, a symmetrical diamidinophenylbithiophene (III) exhibited cellular activity by binding to DNA and inhibiting binding of erythroblast transformation-specific (ETS)-related gene, an ETS family transcription factor that is commonly overexpressed or translocated in leukemia and prostate cancer.[@b25-dddt-8-1659],[@b26-dddt-8-1659] Although thiophene and furan rings are known for their broad biological activities,[@b27-dddt-8-1659] we have shown that replacing one or more furan ring with a thiophene one increased the DNA binding affinity,[@b10-dddt-8-1659] antibacterial, and antioxidant activities.[@b11-dddt-8-1659],[@b28-dddt-8-1659]

Cancer occurs when genetic mutations accumulate in cells during the replication of genetic material, allowing cells to undergo transformation. Recently, a promising antimutagenic activity against sodium azide and benzo\[a\]pyrene-induced mutagenicity was shown for many of fluorinated and non-fluorinated bichalcophenes.[@b29-dddt-8-1659],[@b30-dddt-8-1659] In particular, monocationic bithiophene (IV) has the highest antimutagenic activity, which is superior to other tested bichalcophenes.[@b29-dddt-8-1659]

As part of a research program directed toward the discovery of anticancer drugs, and due to the importance of bithiophenes and oligothiophenes as therapeutic agents, and their unusual DNA binding affinity, we have decided to synthesize new isosteres of compound IV, which showed potent anticancer activity, by changing the location of the amidine group to be attached directly to the bithiophene moiety. Modifications have also included the replacement of a phenyl ring with 4-methoxyphenyl, 3,5-dimethoxyphenyl, and thiophene units. In this report, DNA cleavage and antioxidant activity testing results of the prepared series of cationic bithiophenes and analogues have also been reported and discussed.

Experimental methods
====================

Chemistry
---------

Melting points (mps) were recorded using a Gallenkamp melting-point apparatus and were uncorrected. Thin-layer chromatography analysis was carried out on silica gel 60 F~254~ precoated aluminum sheets and detected under ultraviolet (UV) light. Infrared spectra were recorded using a KBr wafer technique on a Shimadzu 5,800 Fourier transform infrared spectrometer. ^1^H and ^13^C nuclear magnetic resonance (NMR) spectra were recorded using a Varian Mercury VX 300 spectrometer and a Bruker Avance 400 MHz spectrometer, and chemical shifts (δ) were in parts per million, relative to tetramethylsilane as an internal standard. Mass spectra were recorded on a gas chromatography mass spectrometer (Shimadzu GPMS-QP2010 Plus). Elemental analyses were performed using a PerkinElmer 2,400 analyzer at the microanalytical laboratories of the Faculty of Science, Cairo University, and were within ±0.4 of the theoretical values ([Table 1](#t1-dddt-8-1659){ref-type="table"}). All chemicals and solvents were purchased from Sigma-Aldrich Chemical Company and Thermo Fisher Scientific.

### General procedure for preparation of mononitrile bithiophenes 4a--4c

#### 5′-phenyl-2,2′-bithiophene-5-carbonitrile (4a)

To a stirred solution of 5′-bromo-2,2′-bithiophene-5-carbonitrile (2.7 g, 10 mmol) and tetrakis(triphenylphosphine) palladium (190 mg) in toluene (20 mL), 10 mL of a 1.5 M aqueous solution of NaHCO~3~ was added, followed by phenylboronic acid (1.46 g, 12 mmol) in 5 mL of methanol. The vigorously stirred mixture was warmed to 80°C for 16 hours. The product was extracted with ethyl acetate (250 mL, 3×). The organic layer was passed through celite to remove palladium, dried (Na~2~SO~4~), and then concentrated to dryness under reduced pressure, to afford the mononitrile 4a in 78% yield, mp 133°C--134°C (EtOH). R~f~ =0.69, petroleum ether (60°C--80°C)-EtOAc (8:2). IR (KBr) ν' 3,093, 3,021 (CH), 2,216 (CN), 1,610, 1,594, 1,581 (C=C) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 7.35--7.59 (m, 6H), 7.69--7.72 (m, 2H), 7.96 (d, J=4.5 Hz, 1H). MS (EI) m/e (relative intensity \[rel int\]); 267 (M^+^, 100), 233 (21). 152 (41). Analysis (C~15~H~9~NS~2~) C, H, N.

#### 5′-(4-methoxyphenyl)-2,2′-bithiophene-5-carbonitrile (4b)

A yellow solid in 81% yield, R~f~ =0.48, petroleum ether (60°C--80°C)-EtOAc (8:2), mp 154°C--155°C (EtOH/DMF). IR (KBr) ν' 3,089, 2,966, 2,938 (CH), 2,217 (CN), 1,603, 1,594, 1,570 (C=C) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 3.76 (s, 3H), 6.98 (d, J=8.4 Hz, 2H), 7.43--7.46 (m, 2H), 7.51 (d, J=3.8 Hz, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.92 (d, J=4.5 Hz, 1H). MS (EI) m/e (\[rel int\]); 297 (M^+^, 100), 282 (73), 254 (25). Analysis (C~16~H~11~NOS~2~) C, H, N.

#### 5′-(3,5-dimethoxyphenyl)-2,2′-bithiophene-5-carbonitrile (4c)

A yellow solid in 76% yield, mp 160°C--161°C (EtOH/DMF). R~f~ =0.42, petroleum ether (60°C--80°C)-EtOAc (8:2). IR (KBr) ν' 3,097, 3,065, 2,993, 2,940 (CH), 2,214 (CN), 1,585, 1,551 (C=C) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 3.76 (s, 6H), 6.47 (s, 1H), 6.78 (s, 2H), 7.47 (d, J=3.8 Hz, 1H), 7.54 (d, J=3.8 Hz, 1H), 7.59 (d, J=3.8 Hz, 1H), 7.92 (d, J=3.8 Hz, 1H). MS (EI) m/e (rel int); 327 (M^+^, 100), 296 (5). Analysis (C~17~H~13~NO~2~S~2~) C, H, N.

#### α-terthienyl-2-carbonitrile (6)

A mixture of 5′-bromo-2,2′-bithiophene-5-carbonitrile (2.7 g, 10 mmol), 2-(tri-*n*-butylstannyl)thiophene (4.13 g, 11 mmol), and tetrakis(triphenylphosphine)palladium (190 mg) in dry dioxane (20 mL) was heated at reflux (100°C--110°C) for 24 hours. The solvent was evaporated under reduced pressure, the solid was dissolved in ethyl acetate, and the solution was passed through celite to remove palladium. The solution was evaporated, and the solid was filtered and recrystallized from ethanol/pet ether to give compound 6 as a yellow solid in 67% yield, mp 127°C--128°C. R~f~ =0.67, petroleum ether (60°C--80°C)-EtOAc (8:2). IR (KBr) ν' 3,087, 3,065 (CH), 2,215 (CN), 1,601, 1,525 (C=C) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 7.12 (d, J=4.8 Hz, 1H), 7.36 (d, J=3.9 Hz, 1H), 7.42--7.60 (m, 4H), 7.96 (d, J=3.9 Hz, 1H). MS (EI) m/e (rel int); 273 (M^+^, 100). Analysis (C~13~H~7~NS~3~) C, H, N.

### General procedure for preparation of monoamidine bithiophenes and isosters 5a--5c and 7

#### 5′-phenyl-2,2′-bithiophene-5-amidine hydrochloride salt (5a)

The mononitrile bithiophene 4a (401 mg, 1.5 mmol), suspended in freshly distilled THF (8 mL), was treated with LiN(TMS)~2~ (1 M solution in THF, 4 mL, 4 mmol) and the reaction was allowed to stir overnight. The reaction mixture was then cooled to 0°C, to which was added hydrogen chloride ethanolic solution (12 mL, 1.25 M), whereupon a precipitate started forming. The mixture was left to run overnight, whereafter it was diluted with ether, and the resultant solid was collected by filtration. The monoamidine was purified by neutralization with 1N NaOH, followed by filtration of the resultant solid and washing with water. Finally, the free base was stirred with hydrogen chloride ethanolic solution overnight, diluted with ether, and the solid formed was filtered and dried to give the monoamidine 5a hydrochloride salt as a yellow solid in 75% yield, mp 201°C--202°C. IR (KBr) ν' 3,351, 3,200 (NH, NH~2~), 3,081 (CH), 1,657, 1,567 (C=C, C=N, NH bending) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 7.37--7.72 (m, 8H), 8.06 (d, J=3.9 Hz, 1H), 9.21 (br s, 4H, exchangeable with D~2~O). ^13^C NMR (DMSO-*d*~6~); δ 125.4, 125.7, 125.9, 127.0, 128.3, 128.9, 129.7, 133.2, 134.0, 136.0, 144.3, 145.3, 158.8. MS (EI) m/e (rel int); 284 (M^+^, 100), 268 (46). Analysis (C~15~H~12~N~2~S~2~-1.0HCl-1.1H~2~O) C, H, N.

#### 5′-(4-methoxyphenyl)-2,2′-bithiophene-5-amidine hydrochloride salt (5b)

A yellow solid in 70% yield, mp 258°C--260°C. IR (KBr) ν' 3,351, 3,200 (NH, NH~2~), 3,081 (CH), 1,657, 1,567 (C=C, C=N, NH bending) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 3.77 (s, 3H), 7.01 (d, J=8.4 Hz, 2H), 7.45--7.66 (m, 5H), 8.04 (d, J=3.8 Hz, 1H), 9.38 (br s, 2H, exchangeable with D~2~O), 9.08 (br s, 2H, exchangeable with D~2~O). ^13^C NMR (DMSO-*d*~6~); δ 55.8, 115.1, 124.5, 125.0, 125.9, 126.5, 127.4, 128.4, 132.8, 136.0, 144.6, 145.6, 158.7, 160.0. MS (EI) m/e (rel int); 314 (M^+^, 100), 297 (33). Analysis (C~16~H~14~N~2~OS~2~-1.0HCl-1.5H~2~O) C, H, N.

#### 5′-(3,5-dimethoxyphenyl)-2,2′-bithiophene-5-amidine hydrochloride salt (5c)

A golden-yellow solid in 68% yield, mp 251 5°C--252.5°C. IR (KBr) ν' 3,321, 3,200, (NH, NH~2~), 3,093, 2,965 (CH), 1,660, 1,592 (C=C, C=N, NH bending) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 3.78 (s, 6H), 6.49 (s, 1H), 6.80 (s, 2H), 7.54 (d, J=3.8 Hz, 1H), 7.57 (d, J=3.8 Hz, 1H), 7.62 (d, J=3.8 Hz, 1H), 8.03 (d, J=3.8 Hz, 1H), 9.34 (br s, 2H, exchangeable with D~2~O), 9.07 (br s, 2H, exchangeable with D^2^O). ^13^C NMR (DMSO-*d*~6~); δ 55.9, 100.7, 104.2, 125.5, 126.4, 127.0, 128.2, 134.1, 135.0, 136.0, 144.3, 145.1, 158.8, 161.5. MS (EI) m/e (rel int); 344 (M^+^, 100), 327 (76). Analysis (C~17~H~16~N~2~O~2~S~2~-1.0HCl-1.4H~2~O) C, H, N.

#### α-terthienyl-2-amidine hydrochloride salt (7)

A yellow solid in 71% yield, mp 199°C--200.5°C. IR (KBr) ν' 3,326, 3,200, 3,079 (NH, NH~2~, CH), 1,655, 1,568 (C=N, C=C, NH bending) cm^−1^. ^1^H NMR (DMSO-*d*~6~); δ 7.13 (d, J=3.9 Hz, 1H), 7.38 (d, J=3.9 Hz, 1H), 7.42--7.61 (m, 4H), 8.09 (d, J=3.9 Hz, 1H), 9.15 (br s, 2H, exchangeable with D~2~O), 9.42 (br s, 2H, exchangeable with D~2~O). ^13^C NMR (DMSO-*d*~6~); δ 125.5, 125.6, 125.8, 127.0, 127.1, 128.2, 129.1, 133.3, 135.8, 136.0, 138.5, 144.0, 158.8. MS (EI) m/e (rel int); 290 (M^+^, 100), 274 (40). Analysis (C~13~H~10~N~2~S~3~-1.0HCl-1.25H~2~O) C, H, N.

Biology
-------

### In vitro antiproliferative screening

#### Experimental design

The structures of the synthesized compounds were sent to the National Cancer Institute (NCI) (Bethesda, MA, USA) for evaluation of their anticancer activity, where 15 compounds representing 12 monoamidines and three of their cyano precursors were chosen and subjected to a primary in vitro one-dose (10 μM) anticancer assay using the full NCI 60 cell panel, in accordance with the current protocol of the NCI Drug Evaluation Branch. In this protocol, all compounds submitted to the screen were tested initially at a single high dose (10 μM) in the full NCI panel of 60 cell lines, representing nine types of cancer (leukemia, non-small cell lung, colon, central nervous system \[CNS\], melanoma, ovarian, renal, prostate, and breast cancers). A 48-hour continuous drug exposure protocol was used, and a sulforhodamine B (SRB) protein assay was employed to estimate cell viability or growth.[@b40-dddt-8-1659]--[@b42-dddt-8-1659] The data obtained are a mean graph of the percent growth of treated cells, presented as percentage growth inhibition (GI%) caused by the tested compounds ([Table 2](#t2-dddt-8-1659){ref-type="table"}). Only compounds showing high GI% against the majority of the tested cell lines and satisfying predetermined threshold inhibition criteria set forth by the Development Therapeutic Program were selected for progression to the five-dose screen study against the panel of 60 cell lines, and the GI~50~ values against each cell line were determined ([Table 3](#t3-dddt-8-1659){ref-type="table"}) as well as their mean GI~50~, TGI, and LC~50~ values against all tested cell lines, representing the mean graph midpoints ([Table 4](#t4-dddt-8-1659){ref-type="table"}).

#### Experimental procedure

The experiment was performed under sterile conditions, where cell lines were grown in RPMI 1,640 medium (Gibco, NY, USA), supplemented with 10% fetal bovine serum (Biocell, CA, USA); 5×10^4^ cells/mL were used to test the growth inhibition activity of the tested compounds. Cell culture (1.8 mL) containing a cell population of 6×10^4^ cells/mL was pipetted into each well of a 96-multiwell microtiter plate (10^4^ cells/well) 24 hours before treatment with the test compound, to allow attachment of cells to the wall of the plate. For determination of the GI~50~, five serial ten-fold dilutions of each compound, with concentrations ranging from 0.01 μM to 100 μM, were prepared in saline buffer and used for the purpose. Each compound was initially solubilized in dimethylsulfoxide (DMSO); however, each final dilution contains less than 1% DMSO. Solutions of the different concentrations (0.2 mL) were pipetted into separate wells of a microtiter tray, in duplicates, followed by an incubation period of 48 hours at 37°C in an atmosphere of 5% CO~2~. Thereafter, cells were fixed, washed, and stained for 30 minutes with 0.4% (w/v) SRB dissolved in 1% acetic acid. Excess, unbound dye was removed by four washes with 1% acetic acid, and attached stain was recovered with Tris--EDTA buffer. Color intensity was measured in an ELISA reader at a wavelength of 570 nm. Controls, containing only phosphate buffer (PB), saline, and DMSO, at identical dilutions, were also prepared and tested in the same manner.

### Nuclease-like activity assay

Genomic DNA extracted from *E. coli* K91, according to reported methodology,[@b43-dddt-8-1659] was used for the nuclease-like activity assay of the tested bichalcophenes. DNA purity and concentration were examined at 260/280 nm, spectrophotometrically. The bichalcophene compounds were dissolved in DMSO (0.5 mg/mL) and 2 μg, 4 μg, and 6 μg were added individually to 2 μg of the *E. coli* DNA. DNA alone and DNA with DMSO were used as a control. The reactions were carried out at 37°C for 30 minutes. A solution of 10% w/v ficol 400, 0.06% w/v bromophenol blue, and 0.5% w/v SDS was added to the reaction mixtures prior to running the gel. The DNA was analyzed by using horizontal agarose gel electrophoresis. The electrophoresis was performed using 1.0% agarose gel at a constant voltage of 80 V for 60 minutes in TEA buffer (40 mM Tris--HCl pH 7.9, 5 mM sodium acetate, 1 mM EDTA). The agarose gels were stained with ethidium bromide (0.5 μg/mL), visualized under a UV transilluminator, and photographed using a digital camera.

### ABTS radical cation decolorization assay

ABTS \[2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt\] forms a relatively stable free radical, which decolorizes in its non-radical form. The analysis of ABTS^+^ scavenging activity was measured spectrophotometrically, according to the method of Re et al.[@b44-dddt-8-1659] A mixture of ABTS (1 mL, 0.1 g/100 mL) and MnO~2~ (1.5 mL, 25 mg/mL), prepared in PB (pH 7.4, 100 mM) was vortexed, centrifuged, and decanted. Prior to assay, the resulting green-blue solution was diluted in PB to give an absorbance (A~control~ of ABTS radical solution) at 734 nm of 0.600 in a 1 cm cuvette, and equilibrated to 30°C (the temperature at which all the assays were done). Antioxidant activities of the tested bichalcophenes were estimated from the radical cations of ABTS. The absorbance (A~test~) was measured upon the addition of 2 μg of the bichalcophenes in DMSO/PB (1:1 v/v) to the ABTS mixture. Ascorbic acid was used as a standard antioxidant (positive control). Blank samples were run by solvent without ABTS. The decrease in absorbance is expressed as % inhibition, which is calculated from the following formula: $$\%\ \text{inhibition} = (\lbrack A_{\text{control}} - A_{\text{test}}\rbrack/A_{\text{control}}) \times 100$$

where A~control~ is the absorbance of the control reaction (containing all reagents except the test compound) and A~test~ is the absorbance of the test compound. All data about total antioxidant activity are the averages of triplicate analyses.

### Nitric oxide scavenging assay

A nitric oxide scavenging activity assay was carried out according to the reported methodology,[@b45-dddt-8-1659] where sodium nitroprusside generates NO radicals, which interact with oxygen to produce nitrite ions. These can be estimated using the Greiss reagent \[1% sulfanilamide, 2% H~3~PO~4~, and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride\]. Scavengers of NO compete with oxygen, leading to less production of nitrite ions. For the experiment, sodium nitroprusside (10 mM) in PB saline was mixed with bichalcophenes (2 μg) and standard. The reaction mixtures were incubated at room temperature for 150 minutes at 25°C and, after that, 0.5 mL of Griess reagent was added. The absorbance of the pink color formed during diazotization of nitrite with sulfanilamide and subsequent coupling with naphthylethylenediamine was read at 546 nm and referred to the absorbance of standard solutions of sodium nitrite, treated in the same way with Griess reagent.[@b46-dddt-8-1659] Nitric oxide scavenging activity was calculated by the following equation: $$\%\ \text{nitric~oxide~scavenging~activity} = \lbrack(A_{\text{control}} - A_{\text{test}})/A_{\text{blank}}\rbrack \times 100$$

where A~control~ is the absorbance of the control reaction (containing all reagents except the test compound) and A~test~ is the absorbance of the test compound. All data about total antioxidant activity are the average of triplicate analyses.

### Total antioxidant activity determination in linoleic acid emulsion

The antioxidant activity of the bichalcophene compounds was determined according to the reported ferric thiocyanate methodology.[@b47-dddt-8-1659] The bichalcophenes (2 μg/mL in DMSO/PB v:v 1:1) was prepared and added to 2.5 mL of linoleic acid emulsion in PB. The linoleic acid emulsion was prepared by homogenizing 15.5 μL of linoleic acid, 17.5 mg of Tween-20 as emulsifier, and 5 mL PB. The control was composed of 2.5 mL of linoleic acid emulsion and 2.5 mL PB. The reaction mixture (5 mL) was incubated at 37°C for 30 minutes. The peroxide levels were determined by recording the absorbance at 500 nm after reaction with FeCl~2~ and SCN, at intervals during incubation. The peroxides formed during linoleic acid peroxidation oxidize Fe^2+^ to Fe^3+^, which forms a complex with SCN that has a maximum absorbance at 500 nm. Therefore, high absorbance indicates high linoleic acid oxidation. The solutions without added bichalcophenes or standards were used as blank samples. The percent inhibition of lipid peroxidation in linoleic acid emulsion was calculated by the following equation: $$\%\text{inhibition~of~lipid~peroxidation} = 100 - (A_{\text{test}}/A_{\text{control}} \times 100)$$

where A~control~ is the absorbance of the control reaction, which contains only linoleic acid emulsion and PB. A~test~ is the absorbance of the sample in the presence of bichalcophene compounds. All data about total antioxidant activity are the average of triplicate analyses.

Results and discussion
======================

Chemistry
---------

Monocationic bichalcophenes (1a--1j) and mononitrile bichalcophenes (2a--2c) ([Figure 2](#f2-dddt-8-1659){ref-type="fig"}) were prepared according to our previously-reported methodology.[@b11-dddt-8-1659],[@b30-dddt-8-1659] The synthesis of novel monocationic bithiophene derivatives (5a--5c) begins with the Suzuki coupling reaction of 5′-bromo-2,2′-bithiophene-5-carbonitrile with the corresponding phenylboronic acid derivatives to furnish the mononitrile bithiophene derivatives (4a--4c) ([Figure 3](#f3-dddt-8-1659){ref-type="fig"}). The mononitriles were converted to the corresponding monoamidines by the action of lithium trimethylsilylamide \[LiN(TMS)~2~\] in tetrahydrofuran (THF). Whereas, the α-terthienyl-2-amidine (7) was synthesized in two steps, starting with Stille coupling reaction of 5′-bromo-2,2′-bithiophene-5-carbonitrile with 2-(tri-*n*-butylstannyl) thiophene to yield α-terthienyl-2-carbonitrile, followed by direct treatment with LiN(TMS)~2~. The newly synthesized compounds (4a--4c, 5a--5c, 6, and 7) were assigned based on their spectral and elemental analyses.

Biology
-------

### In vitro antiproliferative screening

A series of 15 monocationic bithiophenes and isosteres was subjected to an in vitro antiproliferative screening against a panel of 60 cell lines, representing nine cancer types (leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancers) at the NCI. The standard practice is testing the chosen compounds at an initial high dose (10 μM). Thereafter, the compounds showing satisfactorily high percent growth inhibition (GI%) of the tested cell lines (ten, in this research work) are subjected to a five-dose screen against the panel of 60 cell lines, and their half maximal inhibitory concentration (IC~50~) values are determined.

[Table 2](#t2-dddt-8-1659){ref-type="table"} shows the mean percent growth inhibition (MPGI) results for the initial, single-dose screen against the panel of 60 cancer cell lines, exhibited by the 12 monoamidines plus three of the mononitrile intermediates that were selected by NCI for a primary evaluation of activity of these derivatives. As a beginning, it was found that the mononitrile precursors exemplified by 2a--2c displayed MPGIs of 2.87, 24.34, and 24.85, respectively. These mononitrile derivatives were far less active than their monoamidine derivatives (1c--1e**)**, which elicited MPGI values of 66.06, 72.51, and 75.61, respectively. For that reason, the mononitrile derivatives were not progressed to the five-dose screen. These primary results clearly indicate that the presence of the amidine group plays a fundamental role in the antiproliferative activity of this class of compounds.

A close look at the structure--activity relationship findings among the 12 monoamidine derivatives gave insight about the structural features associated with enhanced antiproliferative activity of this class of compounds. First, it was shown that the bioisosteric replacement of a thiophene ring by a furan leads to a reduction in antiproliferative activity, the effect being more profound upon substitution of the two thiophene rings by furans. This is evidenced by the witnessed MPGI results of the bithiophene 1a (83.98), the thienofuran 1e (75.61), and the bifuran analogue1b (41.95). A similar pattern was observed for the analogues of 1a, 1e, and 1b, where the corresponding aza derivatives displayed MPGI of 66.06 (for the bithiophene 1c), 9.78 (for the thienofuran 1g), and 3.70 (for the bifuran 1j). Also, the fluorophenylbithiophene 1d and bifuran 1f counterparts followed the same behavior (MPGI: −72.51 and −3.16, respectively).

Studying the effect of substitution on, or isosteric replacement of, the phenyl ring of the phenylbichalcophenes, it was found that the aza analogues having a pyridyl ring in the place of the phenyl, suffered a decrease in MPGI, as evidenced by the isosteric pairs 1a/1c, 1e/1g, and 1b/1j. On the other hand, fluorine substitution on the phenyl ring leads to a profound enhancement of antiproliferative activity, as shown by the isosteric pairs 1a/1b and 1d/1f, even turning these derivatives from only being cytostatic to being cytotoxic (having negative MPGI values). This may be explained in terms of the fluorine substitution leading to the seemingly orthogonal effects of increasing local polarity and molecular hydrophobicity, consequently changing their pharmacokinetic properties.[@b31-dddt-8-1659],[@b32-dddt-8-1659]

Attempting to understand the effect of positional isomerism on the antiproliferative effect of these derivatives, a number of compounds (5a--5c and 7), where the amidine moiety was moved from the phenyl to the thiophene side, were prepared. Biological screening data of 5a (MPGI =−52.81), the positional isomer of 1a (MPGI =83.98), demonstrated not only a potentiation of the antiproliferative efficacy but also a great enhancement of cytotoxic activity of this analogue. Indeed, this was the case for the 4-methoxyphenyl derivative 5b (MPGI =−71.27) and the 3,5-dimethoxyphenyl analogue5c (MPGI =−75.15), still having the amidine functionality on the thiophene ring and showing even more enhancement of their cytotoxic abilities compared to 5a. Finally, bioisosteric replacement of the phenyl ring in 5a by a third thiophene ring (in 7) led to a slight decrease in MPGI but still maintained the compound's cytotoxic power.

On the other hand, [Table 3](#t3-dddt-8-1659){ref-type="table"} displays the individual GI~50~ values (drug concentration that causes 50% inhibition of cell growth) of the ten monoamidine derivatives that were promoted for a 5-dose screen, due to their high antiproliferative profiles demonstrated in the primary single-dose screening assay against a panel of 60 cancer cell lines. Among the nine types of cancer involved in this assay, non-small cell lung cancer cell lines were the most responsive to the antiproliferative effect of the tested monoamidines, especially the A549/ATCC, NCI-H322M, and NCI-H460 cell lines. Particularly, derivatives 1a, 1c, 1d, and 7 showed profound growth-deterring power against these three cell lines, with GI~50~ values in the nanomolar scale, in a range of less than 10 nM to 102 nM. In addition, compounds 1c and 1d showed good activity against the MDA-MB-468 breast cancer cell line, with GI~50~, values of 73 nM and 79 nM, respectively.

Finally, [Table 4](#t4-dddt-8-1659){ref-type="table"} depicts the median GI~50~, TGI (concentration causing 100% growth inhibition of tested cells), and LC~50~ (concentration causing 50% lethality of tested cells) of the compounds tested in the five-dose screen. The most active compounds, in compliance with the primary one-dose cell growth percent inhibition assay, were found to be 5b, 5c, 1d, and 7, displaying sub-micromolar GI~50~ values of 0.30 μM, 0.52 μM, 0.63 μM, and 0.95 μM, respectively. All the other compounds exhibited GI~50~ values below 2 μM, except for 1b (GI~50~ =3.71 μM), which was the least active in the primary single-dose screen assay. The most potent amidine in this study was 5b, showing a submicromolar TGI of 0.71 μM and LC~50~ of 2.39 μM. The terthienyl derivative 7 comes second, with a TGI of 2.51 μM and LC~50~ of 7.58 μM. In spite of the fact that 1d showed high potency with regard to its growth inhibitory abilities, reflected in its GI~50~ and TGI values (0.63 μM and 1.99 μM, respectively), yet it was the least cytotoxic in this series, with an LC~50~ of 48.9 μM. Finally, derivative 1b, which had the lowest MPGI among the ten monocationic compounds selected for the five-dose screening assay, was still the least potent with regards to the two measured parameters, GI~50~ and TGI.

### DNA affinity and DNA cleavage ability

The nuclease-like and cleavage efficiency of the bichalcophene compounds, compared to that of controls, is due to their efficient DNA binding and degradation ability. The tested bichalcophenes were allowed to interact with genomic DNA isolated from *Escherichia coli* for cleavage study. In the present investigation, the bichalcophenes have shown increase in nuclease-like activities in a concentration- dependent manner, which illustrates their binding ability with genomic DNA ([Figure 4](#f4-dddt-8-1659){ref-type="fig"}). The nuclease-like activity of the bichalcophenes was investigated under aerobic conditions at 37°C and in the absence of any external additives. The experimental observations demonstrated that the bichalcophene compounds have promising ability toward the cleavage of genomic DNA. The obtained results showed that the examined monocationic bichalcophenes, at 4 μg and 6 μg, are strongly capable of degrading the DNA ([Figure 4B and C](#f4-dddt-8-1659){ref-type="fig"}), while at 2 μg, the monocationic bichalcophenes exhibited weak degradation effect on the DNA ([Figure 4A](#f4-dddt-8-1659){ref-type="fig"}). After 30 minutes of incubation, genomic DNA was strongly degraded at 4 μg of monocationic bithiophene derivatives 1a, 1d, 1e, 5b, 5c, and 7, while at 6 μg of these compounds, the genomic DNA was completely degraded ([Figure 4B and C](#f4-dddt-8-1659){ref-type="fig"}). On the other hand, the observed DNA smear with the monocationic bifuran derivatives 1b, 1f and, 1j, at 6 μg, may be due to their cytostatic binding aptitude. In contrast, the mononitrile bichalcophene compounds 2a, 2b, and 2c**,** at 2 μg, 4 μg, and 6 μg, did not exhibit any nuclease-like activity toward the genomic DNA, as represented ([Figure 4A--C](#f4-dddt-8-1659){ref-type="fig"}). The weak DNA cleavage ability of the mononitriles 2a--2c, compared against the corresponding monoamidines, may be attributed to the differences in pharmacokinetic properties of the nitrile group and the amidine group. These results indicate that the DNA cleavage activity of bichalcophene compounds depends on the structure and the concentration of the examined bichalcophenes. The monocationic bichalcophenes doses utilized in DNA cleavage were high, compared against cellular doses, because DNA cleavage is a qualitative study, while the cellular assay is quantitative. The data on DNA cleavage by bichalcophenes were in agreement with those previously reported.[@b11-dddt-8-1659] It was noted that replacing one or more of the furan rings with a thiophene ring results in an increase in the DNA cleavage affinity, as witnessed in the pattern displayed by the bifuran 1b, the thienofuran 1e, and the bithiophene 1a ([Figure 4A--C](#f4-dddt-8-1659){ref-type="fig"}). This result is consistent with the increased affinity of other thiophene-based amidines, in comparison to furan counterparts, and this may be attributed to the differences in van der Waals radii between S and O atoms.[@b10-dddt-8-1659],[@b33-dddt-8-1659] The weak DNA cleavage ability of the aza derivatives 1g and 1c, compared against the phenyl counterparts 1e and 1a ([Figure 4B](#f4-dddt-8-1659){ref-type="fig"}), is consistent with the decreased affinity of other aza analogue-based amidines, in comparison to phenyl counterparts.[@b34-dddt-8-1659] The reduction in the cleavage affinity of the aza analogues is consistent with their increased hydrophilic properties, as a result of the presence of nitrogen atoms. This result suggests the importance of the hydrophobic component for minor groove DNA binding affinity.[@b16-dddt-8-1659],[@b34-dddt-8-1659] The monocationic bichalcophene compounds have attracted special attention as endonuclease mimics, due to their interesting structural features and the importance of bichalcophene curvature structure for its interaction with the human telomeric quadruplex sequence, with a recently reported, unique CD exciton-type splitting pattern.[@b35-dddt-8-1659] A previously reported finding suggested that dicationic bifuran molecule DB832 can form a stacked molecular complex[@b35-dddt-8-1659] and can bind with the quadruplex.[@b17-dddt-8-1659]--[@b19-dddt-8-1659] Two mechanisms have been hypothesized from the DNA study. The first hypothesis is that monocationic bichalcophenes may bind to the DNA, forming a complex,[@b35-dddt-8-1659] thus preventing DNA from further interacting with ethidium bromide; therefore, the monocationic bichalcophene-DNA adduct was not visualized in the agarose gel. The second postulated mechanism of DNA cleavage is through a hydrolytic pathway.[@b11-dddt-8-1659],[@b36-dddt-8-1659],[@b37-dddt-8-1659] We excluded the oxidative DNA damage mechanism, due to the good antioxidant properties of monocationic bichalcophenes. The present study demonstrates that the monocationic bichalcophenes 1a, 1d, 1f, 1e, 5b, 5c, and 7 have a significant nuclease-like activity toward the cleavage of genomic DNA, in the absence of any external additives, at low concentrations. The DNA cleavage activity without any additive is an appreciated feature of the monocationic bichalcophenes, as promising chemotherapeutic agents in anticancer treatments.

### Antioxidant activity

Since the DNA binding experiments conducted so far have revealed that the monocationic bichalcophenes exhibit good DNA binding affinity, it was considered worthwhile to study the antioxidant activity of this promising type of compound. The ABTS assay is widely used for assessing the ability of ABTS^+^ radical scavenging activity. Because of the presence of a relatively stable free radical cation, the ABTS assay shows a strong absorption band at 734 nm in the visible spectrum. The antioxidant activities of 15 bichalcophenes were evaluated, and the highest bichalcophenes scavenging effects with ABTS radical were in the order 1a\>5a\>5c\>1d\>1e\>1b, as represented in [Table 5](#t5-dddt-8-1659){ref-type="table"}, whereas, compounds 1c, 1f, 1g, and 7 displayed good activity. The monocationic bithiophenes 1a, 5a, 5c, and 1d exhibited better activity, compared against the other bichalcophenes. On the other hand, the mononitrile compounds 2a, 2b, and 2c showed weak scavenging activities with ABTS ([Table 5](#t5-dddt-8-1659){ref-type="table"}), and this result is consistent with their weak DNA cleavage and antiproliferative activities. Thus, it would appear that introducing an amidine group, or replacing a furan ring with a thiophene unit, enhances the antioxidant properties of bichalcophene moieties.

The bichalcophene compounds were also tested for their antioxidant property by the nitric oxide scavenging activity assay technique ([Figure 5](#f5-dddt-8-1659){ref-type="fig"}). The monocationic bichalcophenes 1a, 1b, 1c, 1d, 1e, 5a, 5b, and 5c showed good radical scavenging activity. The other monocationic bichalcophenes 1f, 1g, 1j, and 7 showed moderate antioxidant activity, whereas, the mononitrile bichalcophenes 2a, 2b, and 2c displayed weak nitric oxide scavenging, compared against the control. The ability of the monocationic bichalcophenes to counteract the effect of NO formation represents an opportunity of considerable interest in preventing the severe effects of excessive NO generation in the biological system. This study demonstrated that monocationic bichalcophenes are potent scavengers for NO. Nitric oxide has been recognized to have a significant functional role in a diversity of physiological systems. Nitric oxide is a short-lived free radical, produced nonenzymatically, that causes damage in most biomolecules, including DNA and protein. Nitric oxide is involved in inflammation, cancer, and other pathological conditions.[@b38-dddt-8-1659] Nitric oxide generated from sodium nitroprusside reacts with oxygen to form nitrite. Therefore, monocationic bichalcophenes may inhibit nitrite formation by competing with oxygen to react with nitric oxide.

The presence of antioxidant substances in the antioxidant samples causes the reduction of the Fe^3+^/ferricyanide complex to the ferrous form. Therefore, Fe^2+^ can be monitored by measuring the formation of Perl's Prussian blue at 700 nm.[@b39-dddt-8-1659] The yellow color of the test solution changes to various shades of green and blue, depending on the reducing power of antioxidant samples. The reducing capacity of the bichalcophene compounds may serve as a significant indicator of their potential antioxidant activity. As shown in [Figure 6](#f6-dddt-8-1659){ref-type="fig"}, the bichalcophenes had effective and powerful reducing power, using the potassium ferricyanide reduction method, when compared against the control. For measurement of the reductive ability of the bichalcophenes, the Fe^3+^--Fe^2+^ transformation was investigated in the presence of the bichalcophene compounds. The results on reducing power demonstrate the electron donor properties of the monocationic bichalcophenes, thereby scavenging free radicals by forming stable adducts. The outcome of the redox reaction is to terminate radical chain reactions that may otherwise be very damaging.

The monocationic bichalcophenes exhibited effective antioxidant activity in the linoleic acid emulsion system. The effect of 2 μg of the bichalcophenes on the lipid peroxidation of linoleic acid emulsion is shown in [Figure 6](#f6-dddt-8-1659){ref-type="fig"}. The autoxidation of linoleic acid emulsion, without bichalcophenes or control, was accompanied by a rapid increase in peroxides. Consequently, these results clearly indicated that the monocationic bichalcophenes 1a, 5a, 1d, 5c, and 1b had good antioxidant activity, compared against the control.

Conclusion
==========

Among the 12 monoamidine derivatives, the results of in vitro antiproliferative screening revealed that the bioisosteric replacement of a thiophene ring by a furan leads to a reduction in activity. Studying the effect of substitution on the phenyl ring of the bichalcophene derivatives, or its isosteric replacement by a pyridyl ring, has shown that the analogues having a pyridyl ring in place of the phenyl suffered a decrease in MPGI. In contrast, fluoro substitution on the phenyl ring led to a profound enhancement of the activity. The effect of positional isomerism on the antiproliferative effect of these derivatives was clearly observed. Interestingly, moving the amidine group from the phenyl to the thiophene side increased the activity. Among the nine types of cancer involved in the five-dose screen, non-small cell lung cancer cell lines were the most responsive to the antiproliferative effect of the tested compounds. The most active compounds were found to be 5b, 5c, 1d, and 7, displaying submicromolar GI~50~ values of 0.30 μM, 0.52 μM, 0.63 μM, and 0.95 μM, respectively. The monocationic bichalcophenes have demonstrated promising ability toward cleavage of genomic DNA. Moreover, antioxidant study results have indicated that this series of monocationic bichalcophenes have good antioxidant activity. In general, the monocationic bichalcophenes showed potent antiproliferative activity coupled with good antioxidant and nuclease mimic activities, which can, in part, be considered as the mechanism of action of these compounds. Given the potent in vitro anticancer activity of the monocationic bithiophene derivatives, further in vivo studies are merited, to clarify the real anticancer mechanism of this class of compounds.
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![Biologically important thiophene-based structures.](dddt-8-1659Fig1){#f1-dddt-8-1659}

![Our previously reported bichalcophenes subjected to in vitro antiproliferative screening.](dddt-8-1659Fig2){#f2-dddt-8-1659}

![Newly synthesized bithiophene derivatives.\
**Notes:** Reagents and conditions: (**i**) phenylboronic acid derivatives, Pd(PPh~3~)~4~, NaHCO~3~, toluene, 80°C; (**ii**) LiN(TMS)~2~, THF, room temperature, overnight; HCl (gas), dry ethanol, room temperature, overnight; (**iii**) 2-(tri-*n*-butylstannyl)thiophene, Pd(PPh~3~)~4~, 1,4-dioxane, 100°C--110°C.](dddt-8-1659Fig3){#f3-dddt-8-1659}

![The degradation effect of the bichalcophene series on the genomic DNA isolated from *Escherichia coli* strain K91.\
**Notes:** (**A**) 2 μg; (**B**) 4 μg; (**C**) 6 μg bichalcophene. Lane 1: *E. coli* DNA; Lane 2: *E. coli* DNA + DMSO; Lanes 3--17: *E. coli* DNA + tested bichalcophenes.\
**Abbreviation:** DMSO, dimethyl sulfoxide.](dddt-8-1659Fig4){#f4-dddt-8-1659}

![The nitric oxide scavenging activity of the tested bichalcophenes.](dddt-8-1659Fig5){#f5-dddt-8-1659}

![The activity of the tested bichalcophenes against lipid peroxidation.](dddt-8-1659Fig6){#f6-dddt-8-1659}

###### 

Elemental analysis

  Compound                                      Calculated   Found                         
  --------------------------------------------- ------------ ------- ------ ------- ------ ------
  4a (C~15~H~9~NS)~2~                           67.38        3.39    5.24   67.25   3.50   5.09
  4b (C~16~H~11~NOS~2~)                         64.62        3.73    4.71   64.28   3.67   4.79
  4c (C~17~H~13~NO~2~S~2~)                      62.36        4.00    4.28   62.42   3.79   4.35
  6 (C~13~H~7~NS~3~)                            57.11        2.58    5.12   57.06   2.49   4.83
  5a (C~15~H~12~N~2~S~2~-1.0HCl-1.1H~2~O)       52.88        4.49    8.22   52.71   4.68   8.16
  5b (C~16~H~14~N~2~OS~2~-1.0HCl-1.5H~2~O)      50.85        4.80    7.41   50.89   4.73   7.74
  5c (C~17~H~16~N~2~O~2~S~2~-1.0HCl-1.4H~2~O)   50.27        4.91    6.90   49.99   4.74   7.16
  7 (C~13~H~10~N~2~S~3~-1.0HCl-1.25H~2~O)       44.68        3.89    8.02   44.84   3.97   7.77

###### 

In vitro MPGI of monocationic bichalcophenes against a panel of 60 cell lines at a single dose level (10 μM)

         Compound number                                                                                                            
  ------ ----------------- ------- ------- -------- ------- ------- ------ ------ ------ ------- ------- -------- -------- -------- --------
  MPGI   83.98             41.95   66.06   −72.51   75.61   −3.16   9.78   3.70   2.87   24.34   24.85   −52.81   −71.27   −75.15   −44.71

**Abbreviation:** MPGI, mean percent growth inhibition.

###### 

In vitro antiproliferative activity of monocationic bithiophenes against a panel of 60 cell lines at five-dose level

  Cancer type/cell line            Compound number                                                              
  -------------------------------- ----------------- ------ ------- ------- ------ ------ ------- ------ ------ ---------
  **Leukemia**                                                                                                  
  CCRF-CEM                         1.88              3.11   1.65    0.65    2.33   2.77   1.29    0.2    0.28   1.35
  HL-60 (TB)                       NT^b^             2.19   1.85    0.37    1.82   2.19   0.803   0.21   0.17   1.58
  K-562                            1.76              2.66   1.84    0.22    2.27   1.58   0.243   0.18   0.18   0.553
  MOLT-4                           2.14              3.26   2.06    0.26    2.34   2.27   0.905   0.41   0.23   1.8
  RPMI-8226                        0.157             2.51   0.207   0.23    2.12   1.95   1.63    0.22   0.22   0.338
  SR                               2.31              3.17   1.36    0.23    2.99   1.97   0.291   0.18   0.24   0.302
  **Non-small cell lung cancer**                                                                                
  A549/ATCC                        0.034             4.76   0.017   0.012   1.89   3.04   1.75    0.2    1.03   \<0.010
  HOP-62                           1.54              10.4   1.78    1.29    2.04   2.96   1.89    0.21   1.31   1.74
  HOP-92                           2.32              1.38   0.20    0.17    1.4    9.68   0.809   1.03   0.53   1.06
  NCI-H226                         1.19              14.4   1.57    1.88    2.07   2.61   1.56    2.23   1.77   0.822
  NCI-H23                          1.63              11     3.43    NT      3.63   NT     1.91    NT     NT     1.62
  NCI-H322M                        0.236             3.58   0.102   0.06    2.08   2.1    1.64    0.41   1.17   0.268
  NCI-H460                         0.072             2.43   0.029   0.034   1.79   1.98   1.56    0.20   0.24   \<0.010
  NCI-H522                         1.82              3.73   1.66    1.99    2.1    2.31   1.5     0.26   1.63   1.49
  **Colon cancer**                                                                                              
  COLO 205                         0.514             1.78   0.256   0.19    1.91   1.8    0.475   0.48   0.2    0.208
  HCC-2998                         1.07              1.85   1.06    0.28    1.87   1.94   1.08    0.21   0.21   1.13
  HCT-116                          1.92              3.04   1.54    0.42    1.83   1.69   1.14    1.67   0.17   1.46
  HCT-15                           1.7               2.58   1.89    0.3     1.86   2.02   1.04    0.21   0.29   1.54
  HT29                             1.82              2.79   1.8     0.23    1.89   1.29   0.32    0.18   0.29   1.53
  KM12                             1.72              3.16   1.88    0.49    1.87   1.92   0.563   0.18   0.3    1.47
  SW-620                           1.89              1.92   1.75    0.31    1.77   1.72   1.21    0.18   0.2    1.63
  **CNS cancer**                                                                                                
  SF-268                           1.89              4.85   2.13    1.38    2.19   2.9    1.74    0.20   0.73   1.79
  SF-295                           NT                NT     NT      0.51    NT     1.67   1.59    0.20   0.19   NT
  SF-539                           1.65              8.96   1.45    1.42    1.68   1.6    1.67    0.19   1.38   1.58
  SNB-19                           1.71              9.44   2.38    1.9     2.43   2.48   1.72    0.31   1.59   1.56
  SNB-75                           1.47              10.7   1.95    NT      1.71   1.66   1.36    1.98   1.67   1.77
  U251                             1.72              2.92   1.75    1.07    1.76   1.72   1.27    0.18   0.21   1.71
  **Melanoma**                                                                                                  
  LOX IMVI                         1.88              2.23   1.75    0.41    1.87   1.6    1.21    0.19   0.18   1.74
  MALME-3M                         2.12              2.15   1.98    1.62    1.91   1.74   1.55    1.23   NT     1.71
  M14                              1.9               1.9    1.72    1.37    1.9    1.88   1.68    0.18   0.17   1.55
  MDA-MB-435                       1.74              1.83   1.65    0.29    1.76   1.63   0.497   0.18   0.19   0.407
  SK-MEL-2                         2.38              2.41   2.42    2.27    2.19   2.09   1.92    2.22   1.91   2.08
  SK-MEL-28                        1.79              2.31   1.66    1.43    1.71   1.81   1.59    1.9    1.31   1.69
  SK-MEL-5                         1.63              2.67   1.54    1.25    1.65   1.64   1.64    0.14   1.42   1.02
  UACC-257                         1.84              1.84   1.72    1.56    1.98   1.59   1.63    0.30   1.00   1.66
  UACC-62                          1.68              1.82   1.7     NT      1.75   NT     1.60    NT     NT     1.82
  **Ovarian cancer**                                                                                            
  IGROV-1                          1.84              4.38   1.73    1.5     1.92   2.31   1.61    0.20   0.55   1.76
  OVCAR-3                          0.149             9.77   0.135   1.18    2.25   3.06   1.84    0.19   1.43   NT^b^
  OVCAR-4                          1.71              6.42   1.25    1.2     2.45   2.88   1.72    0.20   0.77   1.03
  OVCAR-5                          1.2               4.98   1.12    1.19    2.02   2.7    1.56    0.22   1.49   1.21
  OVCAR-8                          1.98              8.22   1.68    1.73    2.01   2.31   2.16    0.19   0.21   1.77
  NCI/ADR-RES                      1.78              10.1   2.83    1.77    2.88   2.66   1.96    0.31   0.89   1.79
  SK-OV-3                          13.5              9.21   1.51    1.51    2.4    3.2    1.83    2.14   1.82   1.4
  **Renal cancer**                                                                                              
  786-0                            1.76              3.93   1.63    1.19    1.89   1.74   1.94    0.19   1.39   1.79
  A498                             0.462             6.58   0.274   0.22    1.8    1.36   1.03    1.17   1.39   0.279
  ACHN                             1.70              4.24   1.68    1.41    1.86   1.84   NT      0.19   0.34   1.66
  CAKI-1                           1.70              3.94   1.63    1.59    2.14   1.78   1.57    0.31   1.07   1.57
  RXF 393                          1.34              4.68   1.82    1.13    1.69   1.62   1.16    1.24   0.84   0.29
  SN12C                            1.52              5.97   1.52    1.13    1.97   2.01   1.70    0.20   0.28   1.58
  TK-10                            1.40              4.33   1.03    1.51    1.95   1.69   NT      0.18   0.65   1.48
  UO-31                            0.724             3.17   0.297   1.09    1.90   1.43   1.62    0.16   1.39   0.318
  **Prostate cancer**                                                                                           
  PC-3                             1.64              4.05   1.56    NT      2.13   NT     1.45    NT     NT     1.53
  DU-145                           1.69              6.25   1.72    1.44    1.9    3.27   1.73    0.19   0.47   1.52
  **Breast cancer**                                                                                             
  MCF-7                            1.41              2.08   1.27    0.53    1.69   1.83   1.03    0.19   0.28   0.535
  MDA-MB-231/ATCC                  1.78              2.75   1.62    0.56    1.82   1.60   1.45    0.19   0.25   1.50
  HS-578T                          2.99              4.82   1.55    1.37    2.14   1.53   NT      0.29   0.33   1.85
  BT-549                           1.99              5.9    2.78    1.52    2.05   2.19   1.86    1.66   1.52   1.80
  T-47D                            1.87              2.92   2.11    0.48    2.17   2.05   1.66    0.20   0.38   1.42
  MDA-MB-468                       0.182             1.39   0.073   0.079   1.72   1.57   1.22    0.20   0.23   0.217

**Notes:** Data represent the compounds' GI~50~ in μM against the tested cell lines.

**Abbreviations:** GI~50~, drug concentration that causes 50% inhibition of cell growth; NT, not tested; CNS, central nervous system.

###### 

Median GI~50~, TGI, and LC~50~ for the most active monocationic bithiophenes against a panel of 60 cell lines at five dose level

  MG-MID        Compound number                                                               
  ------------- ----------------- ------- ------- ------ ------ ------- ------ ------ ------- ------
  GI~50~        1.28              3.71    1.07    0.63   1.99   1.94    1.28   0.30   0.52    0.95
  TGI (μM)      3.38              11.48   3.23    1.99   4.26   5.28    2.88   0.71   1.58    2.51
  LC~50~ (μM)   17.78             36.3    10.71   48.9   13.8   17.37   10     2.39   19.05   7.58

**Abbreviations:** MG-MID, mean graph midpoint, representing mean sensitivity of all examined cell lines to the test compound; GI~50~, compound concentration causing 50% growth inhibition of tested cells; TGI, compound concentration causing 100% growth inhibition of tested cells; LC~50~, compound concentration causing 50% lethality of tested cells.

###### 

Antioxidant activity assay (ABTS) of the tested bichalcophene compounds

  Compound number control of ABTS   \% inhibition
  --------------------------------- ---------------
  Ascorbic acid                     86.2
  1a                                70.2
  1b                                61.5
  1c                                57.2
  1d                                64.3
  1e                                61.8
  1f                                54.3
  1g                                52.3
  1j                                56.0
  2a                                27.2
  2b                                19.8
  2c                                21.3
  5a                                65.5
  5b                                60.3
  5c                                66.5
  7                                 56.3

**Abbreviation:** ABTS, 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt.
